AEDS
MCID: ART153
MIFTS: 50

Arthrochalasia Ehlers-Danlos Syndrome (AEDS)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Arthrochalasia Ehlers-Danlos Syndrome

MalaCards integrated aliases for Arthrochalasia Ehlers-Danlos Syndrome:

Name: Arthrochalasia Ehlers-Danlos Syndrome 52 58
Ehlers-Danlos Syndrome, Arthrochalasia Type 52 58 71
Arthrochalasis Multiplex Congenita 52 58
Aeds 52 58
Ehlers-Danlos Syndrome Arthrochalasia Type 36
Ehlers-Danlos Syndrome Type 7 58
Arthrochalasia Eds 52
Eds Vii 58

Characteristics:

Orphanet epidemiological data:

58
arthrochalasia ehlers-danlos syndrome
Inheritance: Autosomal dominant; Age of onset: Infancy,Neonatal;

Classifications:

Orphanet: 58  
Rare systemic and rhumatological diseases
Rare skin diseases
Developmental anomalies during embryogenesis


Summaries for Arthrochalasia Ehlers-Danlos Syndrome

NIH Rare Diseases : 52 Arthrochalasia Ehlers-Danlos syndrome (aEDS) is an inherited connective tissue disorder that is caused by defects in a protein called collagen . Common symptoms include severe joint hypermobility ; congenital hip dislocation ; fragile, hyperextensible skin ; hypotonia ; and kyphoscoliosis (kyphosis and scoliosis ). EDS, arthrochalasia type is caused by changes (mutations ) in the COL1A1 gene or the COL1A2 gene and is inherited in an autosomal dominant manner. Treatment and management is focused on preventing serious complications and relieving associated signs and symptoms.

MalaCards based summary : Arthrochalasia Ehlers-Danlos Syndrome, also known as ehlers-danlos syndrome, arthrochalasia type, is related to scleroderma, familial progressive and ehlers-danlos syndrome. An important gene associated with Arthrochalasia Ehlers-Danlos Syndrome is COL1A1 (Collagen Type I Alpha 1 Chain), and among its related pathways/superpathways are Focal adhesion and ECM-receptor interaction. The drugs Rufinamide and Clobazam have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and brain, and related phenotypes are dysphasia and muscular hypotonia

KEGG : 36 Ehlers-Danlos syndrome arthrochalasia type (EDSARTH) is a rare autosomal dominant disorder that is characterized by severe generalized joint hypermobility, with recurrent joint subluxations and luxations. Congenital bilateral hip dislocation at birth and muscular hypotonia are common.

Related Diseases for Arthrochalasia Ehlers-Danlos Syndrome

Diseases in the Arthrochalasia Ehlers-Danlos Syndrome family:

Ehlers-Danlos Syndrome, Arthrochalasia Type, 1 Ehlers-Danlos Syndrome, Arthrochalasia Type, 2

Diseases related to Arthrochalasia Ehlers-Danlos Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 17350)
# Related Disease Score Top Affiliating Genes
1 scleroderma, familial progressive 31.2 COL1A2 COL1A1
2 ehlers-danlos syndrome 31.1 COL1A2 COL1A1
3 spinal stenosis 31.0 COL1A2 COL1A1
4 bone resorption disease 30.9 COL1A2 COL1A1
5 phenylketonuria 30.9 COL1A2 COL1A1
6 brittle bone disorder 30.9 COL1A2 COL1A1
7 stickler syndrome 30.9 COL1A2 COL1A1
8 marfan syndrome 30.9 COL1A2 COL1A1
9 alport syndrome 30.9 COL1A2 COL1A1
10 dentinogenesis imperfecta 30.8 COL1A2 COL1A1
11 pulmonary fibrosis, idiopathic 30.8 COL1A2 COL1A1
12 osteogenesis imperfecta, type v 30.8 COL1A2 COL1A1
13 caffey disease 30.7 COL1A2 COL1A1
14 osteogenesis imperfecta, type vi 30.7 COL1A2 COL1A1
15 collagen disease 30.6 COL1A2 COL1A1
16 cole-carpenter syndrome 30.6 COL1A2 COL1A1
17 osteogenesis imperfecta, type ii 30.6 COL1A2 COL1A1
18 osteogenesis imperfecta, type i 30.6 COL1A2 COL1A1
19 osteogenesis imperfecta, type iv 30.5 COL1A2 COL1A1
20 connective tissue disease 30.5 COL1A2 COL1A1
21 odontochondrodysplasia 30.5 COL1A2 COL1A1
22 scoliosis 30.5 COL1A2 COL1A1
23 osteogenesis imperfecta, type iii 30.5 COL1A2 COL1A1
24 otosclerosis 30.4 COL1A2 COL1A1
25 bruck syndrome 30.4 COL1A2 COL1A1
26 osteogenesis imperfecta, type vii 30.4 COL1A2 COL1A1
27 ehlers-danlos syndrome, classic type, 1 30.4 COL1A2 COL1A1
28 osteoporosis, juvenile 30.3 COL1A2 COL1A1
29 classic ehlers-danlos syndrome 30.3 COL1A2 COL1A1
30 pelvic organ prolapse 30.1 COL1A2 COL1A1
31 fibrogenesis imperfecta ossium 30.0 COL1A2 COL1A1
32 bone remodeling disease 29.7 COL1A2 COL1A1
33 bone structure disease 29.3 COL1A2 COL1A1
34 bone development disease 29.3 COL1A2 COL1A1
35 diffuse scleroderma 29.2 COL1A2 COL1A1
36 x-linked alport syndrome 29.1 COL1A2 COL1A1
37 col1a1/2 osteogenesis imperfecta 29.1 COL1A2 COL1A1
38 gliofibroma 28.7 COL1A2 COL1A1
39 high bone mass osteogenesis imperfecta 28.2 COL1A2 COL1A1
40 larsen-like syndrome 28.2 COL1A2 COL1A1
41 type i ehlers-danlos syndrome 28.1 COL1A2 COL1A1
42 hypercarotenemia and vitamin a deficiency, autosomal dominant 12.4
43 immunoglobulin a deficiency 1 12.4
44 hepatitis a 12.4
45 hemophilia a 12.4
46 hypervitaminosis a 12.4
47 charcot-marie-tooth disease, recessive intermediate a 12.4
48 molybdenum cofactor deficiency, complementation group a 12.4
49 fanconi anemia, complementation group a 12.3
50 niemann-pick disease, type a 12.3

Graphical network of the top 20 diseases related to Arthrochalasia Ehlers-Danlos Syndrome:



Diseases related to Arthrochalasia Ehlers-Danlos Syndrome

Symptoms & Phenotypes for Arthrochalasia Ehlers-Danlos Syndrome

Human phenotypes related to Arthrochalasia Ehlers-Danlos Syndrome:

58 31 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphasia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002357
2 muscular hypotonia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001252
3 hip dysplasia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001385
4 joint stiffness 58 31 hallmark (90%) Very frequent (99-80%) HP:0001387
5 coxa valga 58 31 hallmark (90%) Very frequent (99-80%) HP:0002673
6 joint hyperflexibility 58 31 hallmark (90%) Very frequent (99-80%) HP:0005692
7 thin skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000963
8 aphasia 58 31 hallmark (90%) Very frequent (99-80%) HP:0002381
9 hip dislocation 58 31 hallmark (90%) Very frequent (99-80%) HP:0002827
10 echolalia 58 31 hallmark (90%) Very frequent (99-80%) HP:0010529
11 coxa vara 58 31 hallmark (90%) Very frequent (99-80%) HP:0002812
12 hyperextensible skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0000974
13 severe short stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0003510
14 avascular necrosis of the capital femoral epiphysis 58 31 hallmark (90%) Very frequent (99-80%) HP:0005743
15 scarring 58 31 hallmark (90%) Very frequent (99-80%) HP:0100699
16 muscle flaccidity 58 31 hallmark (90%) Very frequent (99-80%) HP:0010547
17 mutism 58 31 hallmark (90%) Very frequent (99-80%) HP:0002300
18 abnormality of subcutaneous fat tissue 58 31 hallmark (90%) Very frequent (99-80%) HP:0001001
19 hypertelorism 58 31 frequent (33%) Frequent (79-30%) HP:0000316
20 scoliosis 58 31 frequent (33%) Frequent (79-30%) HP:0002650
21 depressed nasal bridge 58 31 frequent (33%) Frequent (79-30%) HP:0005280
22 micrognathia 58 31 frequent (33%) Frequent (79-30%) HP:0000347
23 retrognathia 58 31 frequent (33%) Frequent (79-30%) HP:0000278
24 epicanthus 58 31 frequent (33%) Frequent (79-30%) HP:0000286
25 inguinal hernia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000023
26 femoral hernia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100541
27 joint dislocation 58 Very frequent (99-80%)

Drugs & Therapeutics for Arthrochalasia Ehlers-Danlos Syndrome

Drugs for Arthrochalasia Ehlers-Danlos Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rufinamide Approved Phase 4 106308-44-5 129228
2
Clobazam Approved, Illicit Phase 4 22316-47-8 2789
3
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
4
Nitrazepam Approved Phase 4 146-22-5 4506
5
Stiripentol Approved Phase 4 49763-96-4
6
Topiramate Approved Phase 4 97240-79-4 5284627
7
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
8
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
9
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
10
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
11
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
12
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
13
Phenobarbital Approved, Investigational Phase 4 50-06-6 4763
14
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
15
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
16
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
17
Haloperidol Approved Phase 4 52-86-8 3559
18
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
19
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
20
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
21
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
22
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
23
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
24
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
25
Probenecid Approved, Investigational Phase 4 57-66-9 4911
26
Vigabatrin Approved Phase 4 60643-86-9, 68506-86-5 5665
27
Citalopram Approved Phase 4 59729-33-8 2771
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
29
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
30
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
31
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
32
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
33
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
34
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
35 Tocotrienol Investigational Phase 4 6829-55-6
36 Vitamins Phase 4
37 GABA-A Receptor Agonists Phase 4
38 GABA Agonists Phase 4
39 Micronutrients Phase 4
40 Trace Elements Phase 4
41 Nutrients Phase 4
42 Antipsychotic Agents Phase 4
43 Hypoglycemic Agents Phase 4
44 Contraceptive Agents Phase 4
45 Hydroxycholecalciferols Phase 4
46 Calciferol Phase 4
47 Tocopherols Phase 4
48 Tocotrienols Phase 4
49 Contraceptives, Oral Phase 4
50 Anti-Infective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 202)
# Name Status NCT ID Phase Drugs
1 Study to Improve the Treatment of Epilepsy (SITE). A Randomized Study Comparing Adjustment of Treatment to Reduce Side Effects of Antiepileptic Drugs With Continuing Treatment Unchanged Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
2 A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs Unknown status NCT02429596 Phase 4 Experimental
3 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
4 A Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Epilepsy in Children Under the Age of Two Years Unknown status NCT02205931 Phase 4 Antiepileptic drug therapy
5 Prospective Open Label Evaluation of Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy: A Pilot Study Unknown status NCT02726919 Phase 4 Clobazam
6 Pregabalin In Partial Seizures (Preps) : An Open-Label, International, Multicenter Add-On Therapy Trial Completed NCT00141427 Phase 4 Pregabalin
7 Phenytoin and Driving Safety Completed NCT00581893 Phase 4 Phenytoin
8 An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine or Carbamazepine for Cognitive Function as Initial Monotherapy in Adult Untreated Epilepsies Completed NCT00896987 Phase 4 lamotrigine (Lamictal);Carbamazepine (Tegretol)
9 EFFECT OF THREE DIFFERENT DOSES OF ORAL CHOLECALCIFEROL (1000 IU, 3000 IU AND 6000 IU DAILY) ON SERUM 25-HYDROXYVITAMIN D CHANGES AMONG EPILEPSY PATIENTS WITH HYPOVITAMINOSIS D: A RANDOMIZED PROSPECTIVE STUDY Completed NCT02890823 Phase 4 Cholecalciferol
10 A Clinical Pharmacokinetics Comparing Brand and Generic Topiramate in Epilepsy Patients : A Open-label,Randomised, Three-period Crossover Study Completed NCT02113787 Phase 4
11 Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy Completed NCT00004637 Phase 4 Vitamin E
12 Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice Completed NCT00855738 Phase 4 Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide
13 Lyrica (Pregabalin) Administered As An Add-On Therapy For Partial Seizures (LEADER) An Open-Label, Multicenter Add-On Therapy Trial Completed NCT00288639 Phase 4 Pregabalin
14 An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures Completed NCT00955357 Phase 4 Lacosamide
15 Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects With Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial Completed NCT03116828 Phase 4 Eslicarbazepine acetate;Eslicarbazepine Acetate
16 Characterization of Epilepsy Patients At-risk for Adverse Outcomes Related to Switching Antiepileptic Drug Products: BEEP 2b Study Completed NCT02707965 Phase 4 Oxcarbmazepine (brand name vs generic drugs);Divalproex Sodium (brand name vs generic drugs);Carbamazepine (brand name vs generic drugs);Lamotrigine (brand name vs generic drugs);levetiracetam (brand name vs generic drugs);Topiramate (brand name vs generic drugs);Zonisamide (brand name vs generic drugs);Phenytoin sodium (brand name vs generic drugs)
17 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study) Completed NCT01733394 Phase 4 Lamotrigine Generic "A" Lamotrigine Generic "B" Lamotrigine "Brand";lamotrigine
18 Women With Epilepsy: a Pilot Study of Pharmacokinetic and Pharmacodynamic Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users Completed NCT02362373 Phase 4 levonorgestrel IUS
19 Searching for "Sleep Friendly" Therapies for a Sleepy Population: A Double-Blind, Placebo-Controlled, Randomized Trial to Assess the Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy Completed NCT01190098 Phase 4 Lacosamide;Placebo
20 Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study - Completed NCT02100644 Phase 4 Lamotrigine tablets 25/100 mg
21 Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design (EQUIGEN Chronic-Dose Study) Completed NCT01713777 Phase 4 Lamotrigine Generic "A";Lamotrigine generic "B"
22 Effect of Small Changes in Plasma Valproic Acid Concentration on the Photoparoxysmal Response Completed NCT00609245 Phase 4 Valproic Acid;Placebo
23 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial Completed NCT03052998 Phase 4 Ivermectin
24 Transcranial Direct Current Stimulation for Treatment of Childhood Pharmacoresistant Lennox-Gastaut Syndrome, A Pilot Study Completed NCT02731300 Phase 4
25 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial Recruiting NCT02334722 Phase 4 Levetiracetam extended release
26 Pharmacokinetics of Antiepileptic Drugs in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy Recruiting NCT03632915 Phase 4 Levetiracetam;Lacosamide;Phenytoin;Phenobarbital;Ketamine;Valproic Acid
27 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
28 Intramuscular Olanzapine Versus Haloperidol or Midazolam for the Management of Acute Agitation in the Emergency Department - a Multicentre Randomised Clinical Trial Recruiting NCT02380118 Phase 4 Olanzapine;Haloperidol;Midazolam
29 Oro-dispersible Olanzapine (Wafer) Versus Conventional Oral Haloperidol or Diazepam Tablets for the Management of Acute Agitation in the Accident and Emergency Department - a Multicentre Randomised Clinical Trial Recruiting NCT03246620 Phase 4 Olanzapine oro-dispersible 5Mg Tab;Haloperidol 2Mg encapsulated Tab;Diazepam 2Mg encapsulated Tab
30 Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Seizure: A Randomized, add-on Placebo-controlled Clinical Trial Recruiting NCT03590197 Phase 4 Melatonin 3 mg
31 Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy (STANDLOW). A Multicenter, Randomized, Single-blind, Parallel-group Trial Not yet recruiting NCT03689114 Phase 4 Low dose carbamazepine;Standard dose carbamazepine;Low dose levetiracetam;Standard dose levetiracetam;Low dose valproate;Standard dose valproate;Low dose zonisamide;Standard dose zonisamide;Low dose oxcarbazepine;Standard dose oxcarbazepine;Low dose topiramate;Standard dose topiramate;Low dose lamotrigine;Standard dose lamotrigine;Low dose gabapentin;Standard dose gabapentin
32 Post Marketing Study; Randomized, Parallel-Group Comparison of Treatment With Pharmacotherapy or Adjunctive Vagus Nerve Stimulation Therapy for Pharmacoresistant Partial Seizures: A Large Simple Effectiveness Trial Terminated NCT00215215 Phase 4
33 An Open Randomized Trial to Assess the Efficacy and Safety of Vagus Nerve Stimulation (VNS) Versus New Anti-Epileptic Drug (AED) Treatment in Children With Refractory Seizures Terminated NCT01118455 Phase 4 Anti-Epileptic Drug (AED)
34 A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability and to Explore the Efficacy of Zonisamide as add-on Therapy in Elderly Patients With Refractory Partial Seizures Terminated NCT01546688 Phase 4 Zonisamide at targeted daily doses of 100-500 mg/day;Placebo administered to match targeted daily doses of 100-500 mg/day
35 An Open Label, Randomized Study Prospectively Examining the Effect on Anxiety in Partial Epilepsy Patients Treated With Pregabalin Terminated NCT01128712 Phase 4 Pregabalin;Pregabalin
36 Evaluating Transporter Protein Inhibitors in Patients With Epilepsy Terminated NCT00610532 Phase 4 phenytoin;phenytoin and probenecid
37 Sabril for Treatment of Adult Refractory Partial Seizures Symptomatic of Tuberous Sclerosis: An Open Label, Phase IV Prospective Safety and Tolerability Study Terminated NCT01266291 Phase 4 vigabatrin
38 Lexapro for Major Depression in Patients With Epilepsy Terminated NCT01244724 Phase 4 Lexapro
39 Efficacy Study of Folic Acid Supplementation on Homocysteine Levels in Adolescent Epileptics Taking Antiepileptic Drugs: A Single Blind Randomized Controlled Clinical Trial Unknown status NCT02318446 Phase 3 Folic Acid;Saccharine
40 A Randomised Controlled Trial in the Palliative Setting Regarding Off-Label Medication: Investigating the Efficiency of Amitriptyline Versus Pregabalin From a Societal Perspective Unknown status NCT00740571 Phase 3 amitriptyline;pregabalin
41 Multicenter, Comparative, Randomized, Open Trial to Evaluate Efficacy and Safety of Levetiracetam Versus Carbamazepine in Post Stroke Late Onset Crisis Unknown status NCT00542802 Phase 3 Levetiracetam;Carbamazepine
42 Double Blind Placebo Controlled Trial of Anticonvulsant Effects of n-3 PUFAs in Human Subjects With Epilepsy Unknown status NCT01769092 Phase 2, Phase 3
43 A Double-Blind, Randomized, Placebo-Controlled Intervention Study of the Efficacy and Safety of "NFM proBio65" in the Atopic and Allergic Volunteers Completed NCT00893230 Phase 3
44 A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effects and Safety, and Pharmacokinetics of Adjunctive Rufinamide Treatment in Pediatric Subjects 1 to Less Than 4 Years of Age With Inadequately Controlled Lennox-Gastaut Syndrome Completed NCT01405053 Phase 3 Rufinamide;Any other approved Antiepileptic Drug
45 Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study Completed NCT01823159 Phase 3 retigabine;placebo
46 An Open-label Extension Trial to Determine Safety and Efficacy of Long-term Oral SPM 927 in Patients With Partial Seizures Completed NCT00522275 Phase 3 lacosamide
47 Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method Completed NCT00160615 Phase 3 Levetiracetam
48 Topiramate (RWJ 17021-000) Clinical Trial In Children With Partial Onset Seizures Completed NCT00236743 Phase 3 topiramate
49 A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures Completed NCT00292461 Phase 3 Zonisamide;Lamotrigine
50 A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures Completed NCT00232596 Phase 3 Retigabine;Placebo

Search NIH Clinical Center for Arthrochalasia Ehlers-Danlos Syndrome

Genetic Tests for Arthrochalasia Ehlers-Danlos Syndrome

Anatomical Context for Arthrochalasia Ehlers-Danlos Syndrome

MalaCards organs/tissues related to Arthrochalasia Ehlers-Danlos Syndrome:

40
Breast, Bone, Brain, Skin, Heart, Lung, Thyroid

Publications for Arthrochalasia Ehlers-Danlos Syndrome

Articles related to Arthrochalasia Ehlers-Danlos Syndrome:

(show all 11)
# Title Authors PMID Year
1
The arthrochalasia type of Ehlers-Danlos syndrome (EDS VIIA and VIIB): the diagnostic value of collagen fibril ultrastructure. 6
18409203 2008
2
Albumin Hawkes Bay; a low level variant caused by loss of a sulphydryl group at position 177. 6
8347685 1993
3
Characterization of a COL1A1 splicing defect in a case of Ehlers-Danlos syndrome type VII: further evidence of molecular homogeneity. 6
1867198 1991
4
Point substitutions in albumin genetic variants from Asia. 6
2404284 1990
5
A base substitution in the exon of a collagen gene causes alternative splicing and generates a structurally abnormal polypeptide in a patient with Ehlers-Danlos syndrome type VII. 6
2767050 1989
6
Deletion of 24 amino acids from the pro-alpha 1(I) chain of type I procollagen in a patient with the Ehlers-Danlos syndrome type VII. 6
3082886 1986
7
Human pro alpha 1(I) collagen gene structure reveals evolutionary conservation of a pattern of introns and exons. 6
6462220 1984
8
The role of arthroscopic thermal capsulorrhaphy in the hip. 61
11675889 2001
9
Generalized hypermobility of joints: arthrochalasis multiplex congenita. 61
4268242 1973
10
Arthrochalasis multiplex congenita. Report of a case. 61
5519306 1970
11
Arthrochalasis multiplex congenita; congenital flaccidity of the joints. 61
13539092 1958

Variations for Arthrochalasia Ehlers-Danlos Syndrome

Expression for Arthrochalasia Ehlers-Danlos Syndrome

Search GEO for disease gene expression data for Arthrochalasia Ehlers-Danlos Syndrome.

Pathways for Arthrochalasia Ehlers-Danlos Syndrome

Pathways related to Arthrochalasia Ehlers-Danlos Syndrome according to KEGG:

36
# Name Kegg Source Accession
1 Focal adhesion hsa04510
2 ECM-receptor interaction hsa04512
3 Relaxin signaling pathway hsa04926

Pathways related to Arthrochalasia Ehlers-Danlos Syndrome according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.32 COL1A2 COL1A1
2
Show member pathways
12.31 COL1A2 COL1A1
3
Show member pathways
12.23 COL1A2 COL1A1
4
Show member pathways
12.16 COL1A2 COL1A1
5
Show member pathways
12.14 COL1A2 COL1A1
6
Show member pathways
12.09 COL1A2 COL1A1
7 11.83 COL1A2 COL1A1
8
Show member pathways
11.7 COL1A2 COL1A1
9 11.59 COL1A2 COL1A1
10
Show member pathways
11.49 COL1A2 COL1A1
11 11.47 COL1A2 COL1A1
12 11.43 COL1A2 COL1A1
13 11.2 COL1A2 COL1A1
14 11.15 COL1A2 COL1A1
15 11.03 COL1A2 COL1A1
16 10.86 COL1A2 COL1A1
17 10.75 COL1A2 COL1A1
18 10.47 COL1A2 COL1A1
19 9.98 COL1A2 COL1A1

GO Terms for Arthrochalasia Ehlers-Danlos Syndrome

Cellular components related to Arthrochalasia Ehlers-Danlos Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 collagen-containing extracellular matrix GO:0062023 9.32 COL1A2 COL1A1
2 endoplasmic reticulum lumen GO:0005788 9.26 COL1A2 COL1A1
3 extracellular matrix GO:0031012 9.16 COL1A2 COL1A1
4 collagen trimer GO:0005581 8.96 COL1A2 COL1A1
5 collagen type I trimer GO:0005584 8.62 COL1A2 COL1A1

Biological processes related to Arthrochalasia Ehlers-Danlos Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix organization GO:0030198 9.48 COL1A2 COL1A1
2 regulation of immune response GO:0050776 9.46 COL1A2 COL1A1
3 leukocyte migration GO:0050900 9.43 COL1A2 COL1A1
4 blood coagulation GO:0007596 9.4 COL1A2 COL1A1
5 skeletal system development GO:0001501 9.37 COL1A2 COL1A1
6 platelet activation GO:0030168 9.32 COL1A2 COL1A1
7 cellular response to amino acid stimulus GO:0071230 9.26 COL1A2 COL1A1
8 blood vessel development GO:0001568 9.16 COL1A2 COL1A1
9 collagen fibril organization GO:0030199 8.96 COL1A2 COL1A1
10 skin morphogenesis GO:0043589 8.62 COL1A2 COL1A1

Molecular functions related to Arthrochalasia Ehlers-Danlos Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent GO:0005201 9.26 COL1A2 COL1A1
2 protease binding GO:0002020 9.16 COL1A2 COL1A1
3 extracellular matrix structural constituent conferring tensile strength GO:0030020 8.96 COL1A2 COL1A1
4 platelet-derived growth factor binding GO:0048407 8.62 COL1A2 COL1A1

Sources for Arthrochalasia Ehlers-Danlos Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....